Bupropion SR for relapse prevention: A "slips-allowed" analysis

Michael J. Durcan, J. Andrew Johnston, Jonathan White, David Gonzales, David P.L. Sachs, Nancy Rigotti, Raymond Niaura

Research output: Contribution to journalArticlepeer-review


Objective: To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis. Methods: Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, double- blind, placebo-controlled relapse prevention study. Results: Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips. Conclusion: Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.

Original languageEnglish (US)
Pages (from-to)456-463
Number of pages8
JournalAmerican Journal of Health Behavior
Issue number5
StatePublished - 2004


  • Bupropion
  • Relapse prevention
  • Slips allowed analysis
  • Smoking cessation

ASJC Scopus subject areas

  • Health(social science)
  • Social Psychology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Bupropion SR for relapse prevention: A "slips-allowed" analysis'. Together they form a unique fingerprint.

Cite this